How many stocks are there of CureVac?
The current number of stocks of CureVac is 220.48 M undefined.
CureVac Stocks 2024
CureVac Stocks
220.48 M
Ticker
CVAC
ISIN
NL0015436031
WKN
A2P71U
In 2024, CureVac had 220.48 M outstanding stocks, a 0% change from the 220.48 M stocks in the previous year.
The CureVac Stocks history
| YEAR | NUMBER OF STOCKS (undefined EUR) |
|---|---|
| 2029e | 220.48 |
| 2028e | 220.48 |
| 2027e | 220.48 |
| 2026e | 220.48 |
| 2025e | 220.48 |
| 2024e | 220.48 |
| 2023 | 220.48 |
| 2022 | 195 |
| 2021 | 187.1 |
| 2020 | 180.5 |
| 2019 | 176.5 |
| 2018 | 176.5 |
CureVac shares outstanding NL0015436031 · A2P71U
The number of shares was CureVac in 2023 — This indicates how many shares 220.481 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
3 years
5 years
10 years
25 Years
Max
Number of stocks
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue CureVac earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates CureVac's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of CureVac’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating CureVac's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
| Number of stocks | |
|---|---|
| 2018 | 176.5 M Aktien |
| 2019 | 176.5 M Aktien |
| 2020 | 180.5 M Aktien |
| 2021 | 187.1 M Aktien |
| 2022 | 195 M Aktien |
| 2023 | 220.48 M Aktien |
| 2024e | 220.48 M Aktien |
| 2025e | 220.48 M Aktien |
| 2026e | 220.48 M Aktien |
| 2027e | 220.48 M Aktien |
| 2028e | 220.48 M Aktien |
| 2029e | 220.48 M Aktien |
CureVac Aktienanalyse
What does CureVac do?
CureVac NV is a German biotechnology company that was founded in 2000 by Ingmar Hoerr, who still leads the company today. The company is headquartered in Tübingen and has a branch in Frankfurt am Main. CureVac's goal is to develop and produce innovative therapies to combat diseases. The history of CureVac began with a focus on the development of RNA-based therapeutics. RNA is a molecule that plays a central role in protein production within the cell. By using RNA in therapeutic applications, the body's own processes can be utilized to fight diseases. CureVac has successfully developed a variety of RNA-based therapeutics in recent years, which are in various stages of clinical development. CureVac's business model is based on providing its technology platform to other companies. These companies can use the platform to develop their own RNA-based therapeutics. CureVac receives fees for this service and also receives a share of any revenues resulting from these projects. CureVac also operates its own pipeline of therapeutic products based on various technologies. One important technology, for example, is the use of messenger RNA (mRNA) to produce proteins that can have a therapeutic effect. CureVac has entered into several partnerships with large pharmaceutical companies such as Sanofi and Boehringer Ingelheim to bring its products to market. The company benefits from the strength of its technology platform and its ability to develop new methods for the production of RNA-based therapeutics. Furthermore, CureVac has played an important role in containing the global COVID-19 pandemic. The company has developed an mRNA vaccine against the SARS-CoV-2 virus, which is approved in Europe. The vaccine has shown to be particularly effective and has a high efficacy against the various variants of the virus. CureVac has signed a contract with the European Union for the delivery of up to 405 million doses of its COVID-19 vaccine, making it an important partner in the fight against the pandemic. Overall, CureVac is a company with a strong focus on RNA-based therapeutics. The company has successfully built a strong technology platform in recent years, enabling other companies to develop their own RNA-based therapeutics. At the same time, CureVac has built its own pipeline of products in various stages of clinical development. The company benefits from the strength of its technology platform and its ability to develop sustainable and effective solutions for various diseases. The success of CureVac, particularly its role in the fight against the COVID-19 pandemic, has shown that RNA technology will play an important role in the future of biotechnology. CureVac ist eines der beliebtesten Unternehmen auf Eulerpool.com.Stocks Details
Evaluating CureVac's Shares Outstanding
CureVac's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.
Year-to-Year Comparison
Tracking the changes in CureVac’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.
Impact on Investments
For investors, understanding CureVac’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.
Interpreting Changes in Shares Outstanding
Variances in CureVac’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.
Frequently Asked Questions about CureVac stock
What does Number of Shares / OutstandingShares mean?
The outstanding shares (or issued shares) of CureVac are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.
How has the number of shares of CureVac evolved in recent years?
The number of shares of CureVac has increased by 0% gestiegen compared to last year.
What does the number of shares mean for investors?
The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.
Why does the number of stocks fluctuate?
There are various factors that can lead to a change. CureVac as a company can issue new shares, carry out stock splits or reverse splits.
Does the number of shares have an impact on the performance of CureVac?
There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
How much dividend does CureVac pay?
Over the past 12 months, CureVac paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, CureVac is expected to pay a dividend of 0 EUR.
What is the dividend yield of CureVac?
The current dividend yield of CureVac is .
When does CureVac pay dividends?
CureVac pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of CureVac?
CureVac paid dividends every year for the past 0 years.
What is the dividend of CureVac?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is CureVac located?
CureVac is assigned to the 'Health' sector.
Wann musste ich die Aktien von CureVac kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of CureVac from 12/19/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 12/19/2024.
When did CureVac pay the last dividend?
The last dividend was paid out on 12/19/2024.
What was the dividend of CureVac in the year 2023?
In the year 2023, CureVac distributed 0 EUR as dividends.
In which currency does CureVac pay out the dividend?
The dividends of CureVac are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The CureVac stock can be added to a savings plan with the following providers: Scalable Capital
Andere Kennzahlen von CureVac
Our stock analysis for CureVac Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of CureVac Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
